Market closedNon-fractional

Adaptive Biotechnologies/ADPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Ticker

ADPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Life Sciences Tools and Services

Headquarters

Seattle, United States

Employees

709

ADPT Metrics

BasicAdvanced
$595M
Market cap
-
P/E ratio
-$1.48
EPS
1.34
Beta
-
Dividend rate
$595M
1.34
4.509
4.243
79.502
82.994
-14.57%
-17.10%
-61.58%
3.356
2.17
3.95
-4.044
-5.33%
8.69%
14.61%
8.66%

What the Analysts think about ADPT

Analyst Ratings

Majority rating from 8 analysts.
Buy

ADPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-113.63% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$42M
-8.53%
Net income
-$48M
-31.56%
Profit margin
-113.63%
-25.17%

ADPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.33
-$0.35
-$0.48
-$0.33
-
Expected
-$0.35
-$0.34
-$0.33
-$0.34
-$0.33
Surprise
-4.79%
3.28%
44.91%
-3.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adaptive Biotechnologies stock?

Adaptive Biotechnologies (ADPT) has a market cap of $595M as of July 23, 2024.

What is the P/E ratio for Adaptive Biotechnologies stock?

The price to earnings (P/E) ratio for Adaptive Biotechnologies (ADPT) stock is 0 as of July 23, 2024.

Does Adaptive Biotechnologies stock pay dividends?

No, Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Adaptive Biotechnologies dividend payment date?

Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Adaptive Biotechnologies?

Adaptive Biotechnologies (ADPT) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Adaptive Biotechnologies stock

Buy or sell Adaptive Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing